“Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S53. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/781.